Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
ACS Infectious Diseases|April 6, 2024
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential LiabilitiesHelena I M Boshoff, Katherine Young, Yong-Mo Ahn, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Cell Host & Microbe|February 29, 2020
Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life CyclePaola Favuzza, Manuel de Lera Ruiz, Jennifer K Thompson, et al.
Nature Medicine|January 13, 2026
Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosisBrendan M Crowley, Helena I Boshoff, Aidan Boving, et al.
Viruses|July 27, 2024
Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological ProfilingNadine Alvarez, Gregory C Adam, John A Howe, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
Plos One|February 6, 2026
Efficacy evaluation of the S-adenosylhomocysteine hydrolase inhibitor MSD-914 in rhesus macaques (Macaca Mulatta) challenged with Ebola virus by the intramuscular routeSara C Johnston, Anthony T Ginnetti, Nancy A Twenhafel, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorSteven Harper, John A McCauley, Michael T Rudd, et al.
Ebiomedicine|December 7, 2025
MK-7602: a potent multi-stage dual-targeting antimalarialPaola Favuzza, Josephine Palandri, Manuel de Lera Ruiz, et al.
ACS Infectious Diseases|February 22, 2022
Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic InstitutionsBen Gold, Jun Zhang, Landys Lopez Quezada, et al.
Pageof 11